The newly opened facility will act as the global headquarters for the company’s NDT biz, as well as housing product development, research & development, marketing and operations, Fridley, Minn.-based Medtronic said.
“Having our own space means we’ve firmly committed to Medtronic being a leader in Type II diabetes. Our business expands the population that Medtronic can serve beyond our historical Type I focus. It is our vision to make glucose a vital sign and therefore, the monitoring of glucose to be an essential part of the care pathway. Our employees in Plymouth are directly contributing to that vision and improving lives of our patients. Our vision is to transform diabetes care so people with diabetes can enjoy greater freedom and better health. We’re here to stay. We have a lot of work to do and are humbled by the opportunity to make a difference for this patient population,” VP & non-intensive diabetes therapy group GM Laura Stoltenberg said in prepared remarks.
“We started with a few people who had big ideas on how to make an impact in Type II diabetes. Now, we’re growing quickly and making progress to achieve those dreams. The formation of the NDT business is instrumental in achieving our goal to serve 20 million patients by 2020, moving from a developed market pump and sensor company, into a global holistic diabetes management company,” added diabetes president Hooman Hakami.
Earlier this month, Medtronic said that data from a study of its closed-loop hybrid artificial pancreas, published in the Journal of the American Medical Assn., showed that the system is safe and effectively maintained blood glucose levels within range in Type I diabetes patients age 14 and older.
Results from the 3-month, 124-patient trial had safety endpoints of the incidence of severe hypoglycemia and diabetic ketoacidosis, serious adverse events and device-related serious and unanticipated adverse events. Data from the study was 1st presented in June at the American Diabetes Assn.’s annual meeting.
The artificial pancreas system is designed to use Medtronic’s MiniMed 670G insulin pump, 4th-generation sensors and a control algorithm to automate basal insulin delivery to keep glucose levels in a healthy range as much as possible, 24 hours a day. Efficacy endpoints in the study included time in open vs. closed-loop systems; the percentage of sensor glucose values below, within, and above target range (71-180 mg/dL), including at night; changes in HbA1c, insulin requirements and body weight; and measures of glycemic variability.